Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Benazepril plus hydrochlorothiazide · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Benazepril plus hydrochlorothiazide | DRUG | - |
Inclusion Criteria: * Male or female patients, age 18 or older * Given informed consent * Diagnosed as having mild to moderate essential hypertension Exclusion Criteria: * Severe hypertension * Significant preexisting cardiovascular and cerebrovascular disease * Diabetes mellitus type 1 or poorly...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
Benazepril plus hydrochlorothiazide is a fixed-dose combination treatment for hypertension, also called high blood pressure. It combines an ACE inhibitor with a thiazide diuretic to lower blood pressure. It has been studied in adults with mild to moderate essential hypertension, including a Phase 3 trial in Chinese patients aged 18 years and older.
Benazepril plus hydrochlorothiazide contains benazepril, an ACE inhibitor that targets angiotensin-converting enzyme (ACE), combined with hydrochlorothiazide, a thiazide diuretic. The ACE inhibition component reduces the activity of the renin-angiotensin system, while the diuretic component promotes sodium and water excretion to lower blood pressure.
Benazepril plus hydrochlorothiazide is developed by Novartis AG, which trades under the ticker NVS. Novartis is the company associated with this fixed-dose combination product for hypertension.
Benazepril plus hydrochlorothiazide has been evaluated in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The product is an investigational combination in the context of the listed development program.
Benazepril plus hydrochlorothiazide has been studied in the Phase 3 trial NCT00367094, titled Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension. The trial enrolled 296 participants in China, was randomized and double-blind, and has been completed.